Drugs / CS231295
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07612488 | Jun 2026 → Dec 2027 expected | cancer of unknown primary site | ThalassaX Therapeutics United States Ltd | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06902350 | May 2025 → Apr 2029 expected | adult glioblastoma, small cell lung carcinoma | Chipscreen Biosciences, Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-04-18 | Chipscreen Biosciences, Ltd. | Results AACR 2026 | Dual Breakthroughs in Novel Target ADCs and Small Molecules: Four Original Oncology Pipeline Studies from Chipscreen and Chipscreen Newway Biosciences Accepted for Presentation chipscreen.com ↗
Its unique synthetic lethality mechanism demonstrates significant therapeutic potential for RB1 gene-deficient tumors (such as small cell lung cancer), and the molecule also exhibits anti-tumor angiogenesis effects. |
| 2025-07-31 | Chipscreen Biosciences, Ltd. | Regulatory Chipscreen Biosciences' Brain-Penetrant Aurora B Selective Inhibitor CS231295 Tablet Receives FDA IND Approval, Advancing Global Clinical Development chipscreen.com ↗
Chipscreen Biosciences (USA) Ltd., has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for its innovative drug CS231295 tablet for the treatment of advanced solid tumors. |
| 2024-10-17 | Chipscreen Biosciences, Ltd. | Regulatory Chipscreen Biosciences' Innovative Anti-Tumor Drug CS231295 Tablets： Investigational New Drug (IND) Application Accepted chipscreen.com ↗
The application has been accepted by the Center for Drug Evaluation of National Medical Products Administration of China (Application Number: CXHL2401105、CXHL2401107、CXHL2401108). |
All press releases naming this drug 5 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CS231295 | “CS231295 is a small-molecule, multi-target protein kinase inhibitor that exhibits balanced activity against both Aurora B kinase and VEGFR/PDGFR kinases.” NCT07612488 ↗ |
| Action | Inhibit | “CS231295 is a small-molecule, multi-target protein kinase inhibitor” NCT07612488 ↗ |
| Modality | Small molecule | “CS231295 is a small-molecule, multi-target protein kinase inhibitor” NCT07612488 ↗ |
| Route | Oral | “oral tablet.” NCT06902350 ↗ |